Crucell
Crucell is a biotechnology company specializing in vaccines and biopharmaceutical technologies.
In September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 million in order to collaborate on the development of a flu vaccine. J&J acquired the rest of the company in October 2010, taking its stake to over 95% by February 2011 and delisting the company from stock exchanges two months later.
